On Feb. 16, 2018, JCO Clinical Cancer Informatics (JCO CCI) published its first special collection of articles. This collection highlights ways in which sharing cancer research data is now possible through individual networks, including ASCO’s CancerLinQ®.
Biosimilars have rapidly proliferated in the cancer care landscape, leaving many providers unclear about the full impact these products will have on the care they deliver to patients. “American Society of Clinical Oncology Statement: Biosimilars in Oncology,” published in the Journal of Clinical Oncology, examines a range of issues to help ASCO members better understand the impact of biosimilars on oncology care.
ASCO provided comments to the Federation of State Medical Boards (FSMB) on a proposed position statement entitled “Compounding of Medications by Physicians.” The society appreciates FSMB’s efforts to ensure the safety of compounded medications, but believes that if finalized in its current form, the FSMB’s position statement would lead to confusion among cancer care providers and create barriers to providing chemotherapy to patients with cancer. ASCO urges FSMB to make clarifications and specific edits to the proposal, or to delay final approval of the position statement to allow time for refinements.